Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noting a discrepancy with the metadata company name "Achieve Life Sciences, Inc.") on March 6, 2009. The report addresses a temporary suspension of trading under the registrant's employee benefit plans, specifically the Sonus Pharmaceuticals, Inc. 401(k) Profit Sharing Plan and Trust.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding plan administration rather than a financial performance statement.
Material Changes
- Extension of Blackout Period: The Company extended the previously announced blackout period for its 401(k) plan. The original expected end date of March 8, 2009, was extended to March 30, 2009.
- Plan Restatement: The extension is due to the amendment and restatement of the Plan onto a document provided by Fidelity Investments, which serves as the new Trustee.
- Investment Options: The restated Plan will offer different investment options and will not offer securities of the Company as an investment option.
Guidance, Outlook, and Restrictions
During the extended blackout period (January 11, 2009, through March 30, 2009):
- Participants cannot access accounts to direct or diversify investments.
- Participants cannot obtain loans or distributions from the Plan.
- Directors and executive officers are prohibited from purchasing, selling, or transferring Company common stock or exercising stock options.
The filing does not contain forward-looking financial guidance, management commentary on business outlook, or specific risk factors beyond the trading restrictions.
Investor Verification Checklist
- Verify the correct registrant name (OncoGenex Pharmaceuticals, Inc. vs. metadata "Achieve Life Sciences, Inc.").
- Confirm the new blackout period end date of March 30, 2009, for trading restrictions on insider stock.
- Review the attached Exhibit 99.1 for the full text of the notice sent to directors and officers.
- Check subsequent filings to confirm the completion of the plan restatement with Fidelity Investments.